Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director/PDMR Shareholding

13th Feb 2015 15:39

RNS Number : 9139E
GlaxoSmithKline PLC
13 February 2015
 

Notification of Transactions of

Directors and Persons Discharging Managerial Responsibility

 

Vesting of Conditional Share Awards

 

This notification sets out information relating to the vesting of conditional share awards under the GlaxoSmithKline 2009 Performance Share Plan (the "Performance Share Plan") and the 2009 Deferred Annual Bonus Plan (the "Deferred Annual Bonus Plan").

 

This announcement covers vesting of awards made to Corporate Executive Team members in 2012. It also covers vesting of awards made to senior executives in 2012 who have subsequently been designated as Persons Discharging Managerial Responsibility.

 

2012 Performance Share Plan Awards

The awards made to the individuals listed in the table below were subject to the following performance conditions measured over the three year performance period from 1 January 2012 to 31 December 2014:

 

a) 25% of the award was subject to an adjusted free cash flow target. The Company did not meet the threshold level of performance for adjusted free cash flow for the three year period and therefore the Remuneration Committee has confirmed that this element of the award lapsed in full.

b) 25% of the award was subject to a TSR measure. For the three years ending 31 December 2014, the Company's TSR ranked 10th (i.e. below median) against a comparator group of 10 global pharmaceutical companies including GSK and therefore the Remuneration Committee has confirmed that this element of the award lapsed in full.

c) 25% of the award was subject to an R&D New Products sales measure. The Company achieved New Product Sales above threshold for the three year period and the Remuneration Committee has confirmed that 27% of this element of the award vested, i.e. 6.75% of the total award.

d) 25% of the award was subject to a Business Diversification measure, measuring sales in Vaccines, Consumer Healthcare, Dermatology and Emerging Markets Asia Pacific and Japan. The Company achieved sales above threshold for the three year period and the Remuneration Committee has confirmed that 27% of this element of the award vested, i.e. 6.75% of the total award.

 

Therefore 13.5% of the total award vested.

 

The table below shows the proportion of these Performance Share Plan awards that vested and lapsed on 12 February 2015. This does not include dividends reinvested since the date of grant. These will be subject to a later announcement once the final number of dividend shares has been determined:

 

Awards which have vested

 

Awards which have lapsed

 

Ordinary Shares

ADS

Ordinary Shares

ADS

Sir Andrew Witty*

59,660

382,266

Mr S Dingemans*

22,969

147,172

Dr M Slaoui*

17,510

112,190

Ms D Connelly

7,252

46,463

Mr A Hussain

15,011

96,178

Mr W Louv

5,136

32,912

Mr D Redfern

8,605

55,134

Ms C Thomas

11,282

72,287

Mr P Thomson

5,736

36,756

Mr D Troy

9,518

60,983

Mr P Vallance

21,990

140,899

Ms E Walmsley

13,003

83,314

* denotes an Executive Director

**25% of Sir Andrew Witty's vested shares (i.e., 14,915 ordinary shares) will be held back, "the holding tranche", for an additional two years as agreed with shareholders beginning with his 2012 Performance Share Plan award

 

2012 Deferred Annual Bonus Awards

 

In 2012, the following individuals elected to defer part of their 2011 annual bonus into shares under the Deferred Annual Bonus Plan (Deferred Shares). These awards are matched up to one-for-one depending on the achievement of performance measures (Matching Shares). The performance measures were the same as for the 2012 Performance Share Plan awards described above and were measured over the same three years to 31 December 2014.

 

Individuals could elect whether to defer part of their bonus on a pre or post tax basis. For awards to UK-based individuals, Deferred and Matching shares were granted as nil-cost options over Ordinary Shares. For awards to US-based individuals, awards of Deferred and Matching shares were granted as conditional awards of ADSs (co-investment shares in the case of post tax Deferred Shares for US-based individuals).

 

The table below shows the pre tax Deferred Shares that will vest on the third anniversary of grant, 9 March 2015. This does not include dividends reinvested since the date of grant. These will be subject to a later announcement once the final number of dividends has been determined:

 

Nil Cost Option over Ordinary Shares

 

Conditional Awards of ADSs/ (ADSs)

Vested

Vested

Sir Andrew Witty*

49,575

Mr S Dingemans*

29,286

Dr M Slaoui*

19,555

Ms D Connelly

5,734

Mr W Louv

4,976

Mr D Redfern

12,536

Ms C Thomas

15,396

Mr D Troy

10,284

Mr P Vallance

21,317

Ms E Walmsley

10,643

* Denotes an Executive Director

 

The table below shows the post tax Deferred Shares that will vest on the third anniversary of grant, 12 March 2015. This does not include dividends reinvested since the date of grant. These will be the subject of a later announcement once the final number of dividends has been determined:

Co-Investment Shares (ADSs)

Released

Ms D Connelly

1,240

 

 

For the three year period 1 January 2012 to 31 December 2014, the Company achieved performance as set out in the 2012 PSP section above and the Remuneration Committee has confirmed that 13.5% of the award of Matching Shares will vest on the third anniversary of the award and that the balance lapsed. The table below shows the pre tax Matching Shares that will vest on 9 March 2015, the third anniversary of the Award. This does not include dividends reinvested since the date of grant. These will be subject to a later announcement once the final number of dividend shares has been determined:

 

Nil Cost Option over Ordinary Shares

 

Conditional Awards over ADSs

Vested

Lapsed

Vested

Lapsed

Sir Andrew Witty*

6,693

42,882

Mr S Dingemans*

3,954

25,332

Dr M Slaoui*

2,640

16,915

Ms D Connelly

774

4,960

Mr W Louv

672

4,304

Mr D Redfern

1,692

10,844

Ms C Thomas

2,078

13,318

Mr D Troy

1,388

8,896

Mr P Vallance

2,878

18,439

Ms E Walmsley

1,437

9,206

* Denotes an Executive Director

 

The above nil cost options in respect of Deferred Shares and Matching Shares can be exercised until 9 March 2022. Dividends no longer accrue on these shares post vesting.

 

The table below shows the post tax Matching Shares that will vest on 12 March 2015, the third anniversary of the Award, excluding dividends reinvested since the date of grant as above:

 

Conditional Awards over ADSs

Vested

Lapsed

Ms D Connelly

167

1,073

 

2012 Performance Share Plan Awards to senior executives who have since been designated PDMRs

 

The conditional awards granted in 2012 to senior executives who have since been designated PDMRs, were dependent on EPS performance (50% of the award) and operational performance targets or relative Total Shareholder Return (remaining 50% of award) over the period 1 January 2012 to 31 December 2014.

 

The table below shows the proportion of these Performance Share Plan conditional awards that vested and lapsed on 12 February 2015. This does not include dividends reinvested since the date of grant. These will be subject to a later announcement once the final number of dividends has been determined:

 

 

 

Awards vested

Awards lapsed

Ordinary Shares

Ordinary Shares

Mr R Connor

0

16,180

Mrs V Whyte

0

11,800

Awards vested

Awards lapsed

ADSs

ADSs

Mr N Hirons

0

6,740

 

 

The Company, Executive Directors and PDMRs were advised of these transactions on 13 February 2015.

 

The closing share prices of an Ordinary Share and of an ADS of GlaxoSmithKline plc at the point of vesting on 12 February 2015 were £14.855 and US$45.95 respectively.

 

This notification is made in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

 

 

VA Whyte

Company Secretary

 

13 February 2015

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSEXLFFELFXBBD

Related Shares:

Glaxosmithkline
FTSE 100 Latest
Value8,632.33
Change89.77